With 29,000 employees who are scientists, researchers, communicators, manufacturing specialists and regulatory experts located around the globe, AbbVie is a company that has come up with new approaches to addressing today’s health issues—from life-threatening illness to chronic conditions.
AbbVie may have been founded in 2013, but its roots run deep. In 2013, the company became a separate company from Abbott, though the company shares a common legacy and strong prospects for future success.
Its name represents its connection to the past and the future. When the company became its own company, AbbVie formed a new kind of enterprise—a biopharmaceutical company. It blends the stability, global scale, resources and commercial capabilities of a pharmaceutical company with the focus and culture of a biotech.
Today, every AbbVie employee around the world focus on delivering transformational medicines and therapies that offer significant patient benefits.
“We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company,” says Richard A. Gonzalez, Chairman & CEO.
AbbVie’s Hope for Tomorrow
AbbVie targets specific difficult-to-cure diseases where it can leverage its core R&D expertise to advance science. It is constantly working to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies—and on science itself.
At AbbVie, everyone sees a future full of possibility, where health is in reach and patient lives are improved.
Patients: Making an Impact on More Lives
To understand the patient journey, AbbVie collaborates with peers, academics, clinical experts, front-line practitioners, governments and advocacy groups. This fuels the company to develop and deliver new solutions that truly make a difference.
Science: Finding Better Solutions to the World’s Toughest Challenges
Research and innovation are the cornerstones of AbbVie’s business. It advances leading-edge science through a dynamic and collaborative approach enabling the company to find better solutions for treating the world’s most challenging diseases. It focuses on discovering, developing and delivering drugs in therapeutic areas where it has proven expertise—and can make an impact. This includes:
Partnerships: Working Together To Make a Difference
The company’s partners share its commitment to solving the world’s greatest health needs. That’s why it collaborate with peers, universities, clinical experts, governments and advocacy groups to seek new solutions for its patients throughout the world. By working together, it combines the best efforts, thinking, and resources to find better solutions for patients.
Responsibility: Passionate About Its Work, Responsible In Its Actions
At AbbVie, it’s both what it does and how it does it that matter. It goes beyond medicine, using its resources to improve health care and communities. AbbVie is committed to:
Culture: Fostering Innovation and Discovery
AbbVie is diverse, inclusive organizations with people who reflect the thousands of communities it serves around the world. For everyone in the company, working at AbbVie is more than a job; it’s a purpose that leads to better lives for other people, across the world. When the stakes are as high as a patient’s well-being, the best ideas must rise to the top, no matter where they begin.
The AbbVie Strategy
AbbVie’s combination of focused innovation and commercial scale brings differentiated products to market that benefit patients and healthcare providers. All its employees around the world are united in this mission to deliver a remarkable impact on patients. The company’s mission is to create an innovation-driven, patient-focused specialty biopharmaceutical company capable of achieving sustainable top-tier performance through outstanding execution and a consistent stream of innovative new medicines.
Innovative medicines provide compelling patient benefits, differentiated clinical performance, and economic value. It plans to launch 20 new products or indications by 2020 that elevate the standard of care and address significant unmet needs.
Building on its market leadership, AbbVie will continue to bring its promoted products to patients around the world. The strong track record of execution of the company will be the key to AbbVie’s success.
AbbVie’s strategy includes attracting and developing top talent. It does that by cultivating a culture of innovation that delivers a remarkable impact.
“AbbVie’s strategy is to deliver innovative medicines and to make a remarkable impact on people’s lives. This is the reason for our success and why we’re able to create value for both our patients and our shareholders,” says Richard.
Richard A. Gonzalez is Chairman of the Board and Chief Executive Officer of AbbVie, a global biopharmaceutical company employing approximately 29,000 people and marketing medicines in more than 175 countries. Prior to AbbVie’s separation from Abbott, Mr. Gonzalez was a 30-year Abbott veteran. He served as Executive Vice President, Pharmaceutical Products Group, where he led the global pharmaceutical business, including commercial operations, research and development, and manufacturing. He also served as President and Chief Operating Officer, prior to a brief retirement.